36 related articles for article (PubMed ID: 26805738)
1. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
Yu HA; Sima C; Feldman D; Liu LL; Vaitheesvaran B; Cross J; Rudin CM; Kris MG; Pao W; Michor F; Riely GJ
Ann Oncol; 2017 Feb; 28(2):278-284. PubMed ID: 28073786
[TBL] [Abstract][Full Text] [Related]
2. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Tseng JS; Wang CL; Huang MS; Chen CY; Chang CY; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Wu CW; Yang CT; Chen YM; Chang GC
PLoS One; 2014; 9(9):e107160. PubMed ID: 25215536
[TBL] [Abstract][Full Text] [Related]
3. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
Boye M; Wang X; Srimuninnimit V; Kang JH; Tsai CM; Orlando M; Puri T; Kim JS; Rajan N; Yang JC
Clin Lung Cancer; 2016 Mar; 17(2):150-60. PubMed ID: 26809984
[TBL] [Abstract][Full Text] [Related]
4. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
5. Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK; Li J; Jeong KJ; Shao S; Chen H; Tsang YH; Sengupta S; Wang Z; Bhavana VH; Tran R; Soewito S; Minussi DC; Moreno D; Kong K; Dogruluk T; Lu H; Gao J; Tokheim C; Zhou DC; Johnson AM; Zeng J; Ip CKM; Ju Z; Wester M; Yu S; Li Y; Vellano CP; Schultz N; Karchin R; Ding L; Lu Y; Cheung LWT; Chen K; Shaw KR; Meric-Bernstam F; Scott KL; Yi S; Sahni N; Liang H; Mills GB
Cancer Cell; 2018 Mar; 33(3):450-462.e10. PubMed ID: 29533785
[TBL] [Abstract][Full Text] [Related]
6. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
Schnipper LE; Davidson NE; Wollins DS; Blayney DW; Dicker AP; Ganz PA; Hoverman JR; Langdon R; Lyman GH; Meropol NJ; Mulvey T; Newcomer L; Peppercorn J; Polite B; Raghavan D; Rossi G; Saltz L; Schrag D; Smith TJ; Yu PP; Hudis CA; Vose JM; Schilsky RL
J Clin Oncol; 2016 Aug; 34(24):2925-34. PubMed ID: 27247218
[No Abstract] [Full Text] [Related]
7. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
Myers MP; Stolarov JP; Eng C; Li J; Wang SI; Wigler MH; Parsons R; Tonks NK
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9052-7. PubMed ID: 9256433
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of Clinicopathological Feature and Prognosis for
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
[TBL] [Abstract][Full Text] [Related]
9. [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review].
Li X; Liu X; Gao F; Yin X
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):85-8. PubMed ID: 25676401
[TBL] [Abstract][Full Text] [Related]
10. Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review.
Yan X; Kong J; Wang J; Wang C; Shen H
BMC Pulm Med; 2024 Mar; 24(1):121. PubMed ID: 38448889
[TBL] [Abstract][Full Text] [Related]
11. [Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].
Li X; Yang H; Xu H; Wang S; Gao H
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):52-6. PubMed ID: 26805738
[TBL] [Abstract][Full Text] [Related]
12. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
13. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
14. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Arbour KC; Kris MG; Riely GJ; Ni A; Beal K; Daras M; Hayes SA; Young RJ; Rodriguez CR; Ahn L; Pao W; Yu HA
Cancer; 2018 Jan; 124(1):105-109. PubMed ID: 28940498
[TBL] [Abstract][Full Text] [Related]
15. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
